# Medical Cannabis for Chronic Pain: Function, Life Enjoyment, and Pain Scores > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/medical-cannabis-chronic-pain-function/ > **Published:** 2026-06-24T22:13:54-04:00 | **Last Modified / Clinically Audited:** 2026-10-14T08:56:31-04:00 > **Clinical Summary:** Explore how medical cannabis chronic pain function impacts life enjoyment and activity interference in patients, based on observational study data. --- CED Clinical Relevance #78 Strong Clinical Relevance This is a fresh human observational study in a large state medical-cannabis program with direct chronic-pain counseling relevance. The evidence is still observational and should shape expectations more than it should drive sweeping efficacy claims. Clinical Insight | CED Clinic A new Minnesota medical-cannabis study is clinically useful not because it proves cannabis is a reliable chronic-pain treatment, but because it measures something many patients care about more than a raw pain score: whether pain interferes less with life. In this state-program analysis, improvements in life enjoyment and general activity were more common than improvement in pain intensity alone. That is a meaningful clinical signal. It is still observational program data, not randomized proof of causality, and it sits beside a broader evidence base showing only small short-term pain benefits for some THC-containing products alongside more dizziness, sedation, and nausea. [Chronic Pain](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/)[Medical Cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/)FunctionObservational StudyEvidence Review Audience Pain clinicians, primary-care clinicians, patients, caregivers, and cannabis-medicine clinicians Primary Topic How [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) may affect pain interference, life enjoyment, and daily function in [chronic pain](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/) patients Source [Read the full study](https://pubmed.ncbi.nlm.nih.gov/42303550/) A 2026 Minnesota medical-cannabis study found that many chronic-pain patients reported meaningful improvement in life enjoyment and general activity interference within four months, with pain intensity improving less often. The result is clinically interesting, but it remains observational and should not be treated as proof that [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) works broadly or uniformly for [chronic pain](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/). What This Study Teaches Us This paper teaches that chronic-pain outcomes can look different depending on what you ask. Using the PEG scale, the Minnesota program tracked pain intensity, pain interference with enjoyment of life, and pain interference with general activity. Among patients who entered with moderate-to-severe scores, 54.9% reported at least 30% improvement in life enjoyment within four months, 54.7% reported similar improvement in general activity interference, and 40.8% reported that degree of improvement in pain intensity. That does not prove cannabis caused the change, but it does support a more function-centered conversation about what improvement can mean in chronic-pain care. Why This Matters Chronic-pain treatment often becomes too narrow when success is judged only by a 0-to-10 pain score. Patients usually care about a broader question: whether they can sleep, move, work, think, tolerate activity, and enjoy ordinary life with less interruption from pain. This study matters because it points toward that broader outcome framework. It also matters because it helps balance two common mistakes in cannabis discussions: overstating cannabis as if it simply treats pain, and dismissing it if pain scores do not collapse dramatically. The clinically useful middle ground is function, tolerability, and whether benefits outweigh risks for a specific patient. Study Snapshot Study Type Observational state-program analysis Population Minnesota medical-cannabis program patients enrolled for chronic or intractable pain Outcome Tool PEG scale: pain intensity, enjoyment of life interference, and general activity interference Program Window Patients enrolled between March 2022 and February 2023 Primary Timepoint Within 4 months of first medical-cannabis purchase Life Enjoyment Improvement 54.9% reported at least 30% improvement among moderate-to-severe baseline patients General Activity Improvement 54.7% reported at least 30% improvement Pain Intensity Improvement 40.8% reported at least 30% improvement Product Pattern High THC-to-CBD products were common; flower was the most commonly purchased route Important Limitation Observational self-reported program data, not randomized placebo-controlled evidence Journal Clinical Therapeutics Published June 16, 2026 PMID 42303550 DOI 10.1016/j.clinthera.2026.05.024 Clinical Bottom Line The Minnesota data is worth taking seriously because it suggests some chronic-pain patients report improvement in function-related outcomes, not only pain scores. It is not proof that medical cannabis will work broadly, and it should be interpreted alongside randomized evidence showing only modest average pain benefit and more adverse effects for some THC-containing products. What the PEG Scale Adds The PEG scale asks three connected but different questions: how much pain hurts, how much it interferes with enjoyment of life, and how much it interferes with general activity. That matters because these are not interchangeable outcomes. A patient can still have substantial pain and yet feel less trapped by it if sleep, movement, household activity, work tolerance, or ordinary life participation improves. This study is useful because it captures that distinction rather than treating pain as one isolated number. What the Minnesota Program Data Showed Among patients who began with moderate-to-severe PEG scores, improvement of at least 30% was more common for life enjoyment and general activity interference than for pain intensity itself. That pattern is clinically interesting because it suggests that some patients may perceive meaningful change even when pain does not disappear. The authors also reported that flower was the most commonly purchased product type and that high THC-to-CBD products were common across categories. After adjustment, product purchasing profiles were not clearly associated with PEG-score improvement outcomes. Why the Result Needs Restraint This was not a randomized controlled trial. Patients were not assigned to cannabis versus placebo, outcomes were self-reported, and the cohort included only people who entered and remained in a real medical-cannabis program long enough to generate follow-up data. That means expectation effects, concurrent treatment changes, survivorship in the program, regression to the mean, and other non-cannabis explanations remain possible. The finding is an association inside real clinical practice, not a clean proof that cannabis caused the improvement. How This Fits With the Better-Controlled Evidence The broader randomized evidence remains more modest. A 2026 Annals of Internal Medicine systematic review found that some comparable or high THC-to-CBD products may produce only small short-term pain improvements, with increased dizziness, sedation, and nausea. That contrast matters. The Minnesota data helps clinicians understand what patients report in a regulated program over time, while the randomized trials help calibrate the average treatment effect under controlled conditions. Both are useful, and neither should be treated as the whole story. How Strong Is This Evidence? This is a real-world human study in a regulated state medical-cannabis program, which makes it more clinically informative than anecdote or uncontrolled marketing claims. Its strongest contribution is that it focuses on patient-reported functional interference rather than pain intensity alone. The evidence still sits below randomized placebo-controlled trials because it is observational, self-reported, and exposed to selection and retention bias. Where This Paper Deserves Skepticism The most important skepticism points are straightforward: self-reported outcomes, no randomized comparator, potential survivorship bias, and uncertainty about which product variables actually mattered. The study also cannot tell us whether improvement came from cannabis itself, from other treatment changes, or from a mixture of factors. Readers should resist converting a useful observational signal into a promise of reliable chronic-pain benefit. What This Paper Does Not Show This study does not show that medical cannabis cures chronic pain, that one product type or THC:CBD ratio is best, that function will improve for every chronic-pain patient, or that observational program outcomes override randomized evidence showing only modest average pain benefit. It also does not establish long-term safety, optimal dose, or superiority over other pain-management strategies. How This Fits With the Broader Clinical Conversation Patients and clinicians often talk past each other in chronic-pain care because the word improvement can mean very different things. One person means pain intensity, while another means sleep, activity, work, or [quality of life](https://cedclinic.com/cannabis-policy-enforcement-february-26-2026/). That is why this paper is useful even though it is not definitive. It reframes the discussion around whether pain is dominating a patient’s life less, while still forcing us to keep the limitations of observational data in view. The most defensible chronic-pain cannabis conversation is neither enthusiasm nor dismissal. It is a structured question about function, tolerability, side effects, and whether the patient is actually participating in life more fully. Dr. Caplan’s Take *When I discuss chronic pain treatments, I care about whether the patient can live more of their life, not only whether their pain score moved. A one-point pain change can matter a lot if the patient is sleeping, moving, and functioning better.* *That said, I would not present this Minnesota paper as proof of efficacy. I would present it as a clinically useful observational signal that supports asking better questions and setting more meaningful goals.* What a Careful Reader Should Take Away A careful reader should come away with a middle-position conclusion: medical cannabis may be associated with function-related improvement for some chronic-pain patients, but the evidence is still observational and should be balanced against modest randomized benefit and known side effects. Evidence Interpretation Guide Table of Contents - [How to Read a Function-First Cannabis Pain Study Without Overreading It](#How_to_Read_a_Function-First_Cannabis_Pain_Study_Without_Overreading_It)[A Better Reading Order for This Pain Study](#A_Better_Reading_Order_for_This_Pain_Study) - [The Same Study Can Mean Different Things Depending on the Question Being Asked](#The_Same_Study_Can_Mean_Different_Things_Depending_on_the_Question_Being_Asked)[Function Is a Real Outcome](#Function_Is_a_Real_Outcome) - [Set Better Targets Than Zero Pain](#Set_Better_Targets_Than_Zero_Pain) - [Observational Improvement Is Not Causality](#Observational_Improvement_Is_Not_Causality) - [Pain Care Is Bigger Than Pain Intensity](#Pain_Care_Is_Bigger_Than_Pain_Intensity) - [Functional Gain Must Still Beat Side Effects](#Functional_Gain_Must_Still_Beat_Side_Effects) - [Real-World and Randomized Evidence Answer Different Questions](#Real-World_and_Randomized_Evidence_Answer_Different_Questions) - [Ask Better Follow-Up Questions](#Ask_Better_Follow-Up_Questions) - [What Better Pain-Cannabis Evidence Still Needs](#What_Better_Pain-Cannabis_Evidence_Still_Needs) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) ## How to Read a Function-First Cannabis Pain Study Without Overreading It Chronic-pain studies can look more positive or more negative depending on which outcome is emphasized. A trial or program analysis focused only on pain intensity may understate what some patients experience as meaningful, while a function-forward interpretation can become too enthusiastic if it ignores study design limitations. The right reading keeps both ideas visible at once: function matters, and observational data still has a ceiling. ### A Better Reading Order for This Pain Study **Start with the outcome definition**PEG is not only a pain score. It includes enjoyment of life and general activity interference, which changes what improvement means. **Separate association from proof**Program data can be clinically useful without proving that cannabis directly caused the observed improvements. **Compare with randomized evidence**When a real-world study looks more optimistic than controlled trials, the difference is a cue to interpret carefully rather than to choose one source and ignore the other. **Bring the question back to the patient**The most practical use of this paper is not a sweeping claim about efficacy. It is a better clinical discussion about function, side effects, and whether the patient is genuinely living more fully. The Question This Study Helps Answer When chronic-pain patients use medical cannabis in a regulated state program, do they report less interference with life enjoyment and general activity as well as changes in pain intensity? The Question Patients Usually Need Answered If I try medical [cannabis for chronic pain](https://cedclinic.com/west-virginia-medical-cannabis-program-edibles-expansion/), should I judge success only by whether pain disappears, or by whether I can sleep, move, and participate in life more effectively with acceptable side effects? The Bottom Line This paper supports a better chronic-pain conversation, but not a simpler one. CED Perspective Lens ## The Same Study Can Mean Different Things Depending on the Question Being Asked Scientific papers rarely answer a single question. Patients, clinicians, researchers, and critics can read the same data differently. These evidence-based lenses show where this trial is useful, where it remains uncertain, and how easily it can be overstated. Overview The same paper can matter differently to a pain specialist, a patient with long-standing chronic pain, a skeptic of observational data, or a clinician focused on side-effect tradeoffs. These lenses keep the function-versus-proof distinction visible. #### Function Is a Real Outcome If you live with chronic pain, it is reasonable to care about whether you can sleep, move, cook, work, socialize, and tolerate daily life more effectively, not just whether your pain score falls dramatically. This paper is useful because it validates that broader goal. It still does not guarantee that cannabis will help you specifically, or that benefits will outweigh side effects. Lens takeaway Judge chronic-pain treatments by life function and side effects, not only by a pain number. #### Set Better Targets Than Zero Pain The study supports a more clinically realistic framing of chronic-pain care. Many patients will never reach zero pain, but some may still achieve meaningful improvement in function and activity tolerance. The evidence is not strong enough to justify casual prescribing logic, but it is strong enough to support more careful outcome-setting and follow-up questions. Lens takeaway Use the paper to improve goal-setting, not to erase the need for caution. #### Observational Improvement Is Not Causality A skeptical reader should focus immediately on retention bias, self-reporting, and the fact that patients who stay engaged in a cannabis program may differ from those who leave early. That skepticism is justified. It does not make the paper worthless, but it does keep the result from becoming a blanket efficacy claim. Lens takeaway The study is hypothesis-supporting and clinically suggestive, not causality-settling. #### Pain Care Is Bigger Than Pain Intensity Pain medicine often works best when it focuses on what the patient can do rather than on a single symptom score. This paper supports that broader rehabilitation-minded view. The function signal does not replace the need to monitor sedation, cognition, balance, and dose escalation, but it does help explain why some patients report meaningful benefit despite incomplete pain relief. Lens takeaway A treatment can matter clinically even when it does not erase pain. #### Functional Gain Must Still Beat Side Effects Any function-centered interpretation has to stay honest about risks. If a patient is more sedated, less steady, or cognitively dulled, an apparent gain can disappear quickly. That is why the Minnesota study belongs beside the randomized review showing more dizziness, sedation, and nausea for some THC-containing products. Lens takeaway Function only counts as improvement when side effects do not cancel it out. #### Real-World and Randomized Evidence Answer Different Questions The Minnesota program data asks what patients report in a real medical-cannabis system. The Annals review asks what happens on average in short-term randomized comparisons. Those are different evidence layers. The right interpretation uses both instead of pretending one invalidates the other. Lens takeaway Use program data for context and trials for calibration. #### Ask Better Follow-Up Questions The most useful clinical questions after starting medical cannabis are concrete: sleeping better or worse, moving more or less, needing fewer rescue medications, feeling steadier or more impaired, and whether daily life is actually opening up. That practical follow-up is more valuable than a vague impression that the treatment feels good or bad. Lens takeaway Track function, tolerability, and behavior change with specifics. #### What Better Pain-Cannabis Evidence Still Needs The next step is not more rhetoric about cannabis and pain. It is better comparative studies with clearer product definitions, better follow-up on function, and stronger handling of retention and confounding. Until then, papers like this remain clinically interesting but still incomplete. Lens takeaway Better product-level and function-level evidence is the next real upgrade. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/) Massachusetts Clinical Care & Certification Are you a Massachusetts resident seeking physician-supervised cannabinoid therapy? Learn more about scheduling a telehealth consultation with a certified [Massachusetts medical marijuana doctor](https://cedclinic.com/massachusetts-medical-marijuana-doctor/), or read our step-by-step 2026 guide on [how to get a medical marijuana card in Massachusetts](https://cedclinic.com/how-to-get-a-medical-marijuana-card-in-massachusetts/) to save ~20% on state dispensary taxes. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=Medical+Cannabis+for+Chronic+Pain%3A+Function%2C+Life+Enjoyment%2C+and+Pain+Scores&url=https%3A%2F%2Fcedclinic.com%2Fmedical-cannabis-chronic-pain-function%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fmedical-cannabis-chronic-pain-function%2F) [BlueSky](https://bsky.app/intent/compose?text=Medical+Cannabis+for+Chronic+Pain%3A+Function%2C+Life+Enjoyment%2C+and+Pain+Scores%20https%3A%2F%2Fcedclinic.com%2Fmedical-cannabis-chronic-pain-function%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Benefits of Medical Cannabis in Patients With Pain Registered in the Minnesota Medical Cannabis Program.](https://pubmed.ncbi.nlm.nih.gov/42303550/) Related Reading at CED Clinic Continue exploring the evidence [Endocannabinoid System and Opioids: What a New Review Says About Pain and OUD](https://cedclinic.com/endocannabinoid-system-opioid-use-disorder-review/) CED context on how cannabinoid-pathway pain discussions fit into broader evidence about [pain management](https://cedclinic.com/cbd-cbg-topicals-for-eczema/) and opioid-related care. [Read the pain review](https://cedclinic.com/endocannabinoid-system-opioid-use-disorder-review/) [Cannabinoids for Cancer Pain: New Review Questions the Opioid-Sparing Claim](https://cedclinic.com/opioid-sparing-cancer-pain-cannabinoids-meta-analysis/) Useful companion reading because it shows how cannabinoid pain claims can look weaker under more controlled evidence review. [Compare the evidence](https://cedclinic.com/opioid-sparing-cancer-pain-cannabinoids-meta-analysis/) [Dronabinol for Chronic Low Back Pain: What the Veterans Trial Will Actually Test](https://cedclinic.com/dronabinol-chronic-low-back-pain/) A useful related piece on how a more controlled pain-study design tries to answer product, dosing, and efficacy questions more directly. [See the trial question](https://cedclinic.com/dronabinol-chronic-low-back-pain/) Similar Studies on CEDClinic.com Earlier coverage on closely related evidence When a new paper overlaps with earlier CED Clinic coverage, we preserve the chain instead of hiding the overlap. These links point to older related posts so readers can compare what is new, what is repeated, and how the evidence has moved. Earlier CED coverage on the same Minnesota study [Medical Cannabis Linked to Meaningful Pain-Related Improvements in Large Minnesota Study](https://cedclinic.com/medical-cannabis-linked-to-meaningful-pain-related-improvements-in-large-minnesota-study/) An earlier CED post on the same Minnesota program paper with broader pain-improvement framing. Similar because both posts cover the same June 16, 2026 Clinical Therapeutics study. Different because the current piece centers the function-versus-pain-score question and weighs it explicitly against randomized evidence limits. [Compare the earlier angle](https://cedclinic.com/medical-cannabis-linked-to-meaningful-pain-related-improvements-in-large-minnesota-study/) ## Frequently Asked Questions What is the PEG scale? PEG is a brief pain outcome tool that asks about pain intensity, interference with enjoyment of life, and interference with general activity. What did the Minnesota study report? Among patients with moderate-to-severe baseline PEG scores, 54.9% reported at least 30% improvement in life enjoyment, 54.7% reported similar improvement in general activity interference, and 40.8% reported that level of improvement in pain intensity within four months. Does this study prove medical cannabis works for chronic pain? No. It is observational program data, not a randomized placebo-controlled trial, so it cannot prove cannabis caused the reported improvements. Why does the function angle matter so much? Because many chronic-pain patients care most about whether they can sleep, move, work, and enjoy ordinary life more effectively, not only whether a pain score drops. Did pain intensity improve as much as function-related outcomes? No. In this analysis, improvement in life enjoyment and general activity interference was more common than improvement in pain intensity. What products were commonly purchased in the program? The paper reported that flower was the most commonly purchased product type and that high THC-to-CBD products were common across categories. Did the study identify one best product profile for pain outcomes? No. After adjustment, the product purchasing profiles were not clearly associated with PEG-score improvement outcomes. How does this compare with randomized evidence? A 2026 Annals of Internal Medicine systematic review found only small short-term average pain improvement for some THC-containing products, along with more dizziness, sedation, and nausea. Should patients judge success only by pain relief? Usually not. A more useful judgment includes sleep, activity, [quality of life](https://cedclinic.com/cannabis-policy-enforcement-february-26-2026/), side effects, and whether the patient can participate in life more fully. What is the safest bottom-line interpretation? Medical cannabis may be associated with function-related improvement for some chronic-pain patients, but the evidence remains observational and should be balanced against modest randomized benefit and known side effects. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).